Effect of Collagen Type I or Type II on Chondrogenesis by Cultured Human Articular Chondrocytes

Rutgers, Marijn; Saris, Daniël B.F.; Vonk, Luciënne A.; Rijen, Mattie H.P. van; Akrum, Vanessa; Langeveld, Danielle; Boxtel, Antonette van; Dhert, Wouter J.A.; Creemers, Laura B.

doi:10.1089/ten.tea.2011.0416

Cited by 64 publications

(48 citation statements)

References 35 publications

(39 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This needs to be prevented for clinical applications, when chondrocytes, isolated from patients, need to be expanded for subsequent surgical replacement using biomimetic scaffolds, on engineered tissues [Shakibaei et al, ]. In fact, autologous chondrocyte transplantation (ACT) based on the association of biomaterials with autologous chondrocytes expanded in vitro is used to repair cartilage [Rutgers et al, ], but either the limited source of healthy primary cells and/or dedifferentiation of cells may lead to the failure of tissue repair [Kawasaki et al, ; Marlovits et al, ]. In this study, first of all, we characterized the cells derived from human nasal septum using type II collagen in order to select only chondrocytes [Benya et al, ].…”

Section: Discussionmentioning

confidence: 99%

Biotechnological Chondroitin a Novel Glycosamminoglycan With Remarkable Biological Function on Human Primary Chondrocytes

Stellavato¹,

Tirino²,

Novellis³

et al. 2016

J of Cellular Biochemistry

View full text Add to dashboard Cite

Cartilage tissue engineering, with in vitro expansion of autologus chondrocytes, is a promising technique for tissue regeneration and is a new potential strategy to prevent and/or treat cartilage damage (e.g., osteoarthritis). The aim of this study was (i) to investigate and compare the effects of new biotechnological chondroitin (BC) and a commercial extractive chondroitin sulfate (CS) on human chondrocytes in vitro culture; (ii) to evaluate the anti‐inflammatory effects of the innovative BC compared to extractive CS. A chondrogenic cell population was isolated from human nasoseptal cartilage and in vitro cultures were studied through time‐lapse video microscopy (TLVM), immunohistochemical staining and cytometry. In order to investigate the effect of BC and CS on phenotype maintainance, chondrogenic gene expression of aggrecan (AGN), of the transcriptor factor SOX9, of the types I and II collagen (COL1A1 and COL1A2), were quantified through transcriptional and protein evaluation at increasing cultivation time and passages. In addition to resemble the osteoarthritis‐like in vitro model, chondrocytes were treated with IL‐1β and the anti‐inflammatory activity of BC and CS was assessed using cytokines quantification by multiplex array. BC significantly enhances cell proliferation also preserving chondrocyte phenotype increasing type II collagen expression up to 10 days of treatment and reduces inflammatory response in IL‐1β treated chondrocytes respect to CS treated cells. Our results, taken together, suggest that this new BC is of foremost importance in translational medicine because it can be applied in novel scaffolds and pharmaceutical preparations aiming at cartilage pathology treatments such as the osteoarthritis. J. Cell. Biochem. 117: 2158–2169, 2016. © 2016 The Authors. Journal of Cellular Biochemistry Published by Wiley Periodicals, Inc.

show abstract

Section: Discussionmentioning

confidence: 99%

Biotechnological Chondroitin a Novel Glycosamminoglycan With Remarkable Biological Function on Human Primary Chondrocytes

Stellavato¹,

Tirino²,

Novellis³

et al. 2016

J of Cellular Biochemistry

View full text Add to dashboard Cite

show abstract

“…To enhance the mechanical properties, crosslinking methods are usually applied. Matrices of collagen alone, or in association with cells had shown to improve cartilage regeneration and had beneficial effects on matrix deposition (Lubiatowski et al, ; Rutgers et al, ; Tseng et al, ). The currently available commercialized collagen based matrices include: (i) Zyderm a bovine injectable gel; (ii) Carticel (Genzyme Inc., Cambridge, UK) a porcine derived types I and II collagen matrix; and (iii) CaReS (Arthrokinetics, Essingen, Germany) a type I collagen matrix (Burdick and Mauck, ; Parenteau‐Bareil et al, ).…”

Section: Advanced Therapiesmentioning

confidence: 99%

Management of knee osteoarthritis. Current status and future trends

Ondrésik

Maia

Morais

et al. 2016

Biotech & Bioengineering

View full text Add to dashboard Cite

Osteoarthritis (OA) affects a large number of the population, and its incidence is showing a growing trend with the increasing life span. OA is the most prevalent joint condition worldwide, and currently, there is no functional cure for it. This review seeks to briefly overview the management of knee OA concerning standardized pharmaceutical and clinical approaches, as well as the new biotechnological horizons of OA treatment. The potential of biomaterials and state of the art of advanced therapeutic approaches, such as cell and gene therapy focused primarily on cartilage regeneration are the main subjects of this review. Biotechnol. Bioeng. 2017;114: 717-739. © 2016 Wiley Periodicals, Inc.

show abstract

“…Delaying or inhibiting terminal chondrocyte differentiation of hMSCs toward fibrocartilaginous and/or hypertrophic phenotypes remains a critical challenge for cartilage tissue engineering strategies based on MSCs in vivo since this can result in the formation of repair tissue with inferior mechanical properties compared to native cartilage and/or mineralization of the newly formed tissue [44], [45], [46], [47], [48]. Our hydrogel constructs exhibited clear decreases in collagen type I and X levels over a period of several weeks compared to other similar systems [49], [50], [51], [52]. These findings were further supported by the COL2A1/COL1A1 gene expression ratio on the MMP7-HHACS-lowRGDS-Scl2 hydrogels, which remained high compared to all other hydrogel formulations throughout culture (Fig.6F).…”

Section: Resultsmentioning

confidence: 89%

Enhanced articular cartilage by human mesenchymal stem cells in enzymatically mediated transiently RGDS-functionalized collagen-mimetic hydrogels

et al. 2017

View full text Add to dashboard Cite

show abstract

Effect of Collagen Type I or Type II on Chondrogenesis by Cultured Human Articular Chondrocytes

Cited by 64 publications

References 35 publications

Biotechnological Chondroitin a Novel Glycosamminoglycan With Remarkable Biological Function on Human Primary Chondrocytes

Biotechnological Chondroitin a Novel Glycosamminoglycan With Remarkable Biological Function on Human Primary Chondrocytes

Management of knee osteoarthritis. Current status and future trends

Enhanced articular cartilage by human mesenchymal stem cells in enzymatically mediated transiently RGDS-functionalized collagen-mimetic hydrogels

Contact Info

Product

Resources

About